Cargando…
Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
Background: The UK National Health Service (NHS) propose the use of oxybutynin prior to onabotulinumtoxinA (Botox) in the management of overactive bladder syndrome (OAB). Oxybutynin is costly and associated with poor adherence, which may not occur with Botox. We conducted a cost-utility analysis (CU...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394450/ https://www.ncbi.nlm.nih.gov/pubmed/34444493 http://dx.doi.org/10.3390/ijerph18168743 |
_version_ | 1783743950908030976 |
---|---|
author | Shabir, Habiba Hashemi, Sana Al-Rufayie, Moussa Adelowo, Tayo Riaz, Umar Ullah, Umayair Alam, Benyamin Anwar, Mehreen de Preux, Laure |
author_facet | Shabir, Habiba Hashemi, Sana Al-Rufayie, Moussa Adelowo, Tayo Riaz, Umar Ullah, Umayair Alam, Benyamin Anwar, Mehreen de Preux, Laure |
author_sort | Shabir, Habiba |
collection | PubMed |
description | Background: The UK National Health Service (NHS) propose the use of oxybutynin prior to onabotulinumtoxinA (Botox) in the management of overactive bladder syndrome (OAB). Oxybutynin is costly and associated with poor adherence, which may not occur with Botox. We conducted a cost-utility analysis (CUA) to compare the medications. Methods: we compared the two treatments in quality-adjusted life years (QALYS), through the NHS’s perspective. Costs were obtained from UK-based sources and were discounted. Total costs were determined by adding the treatment cost and management cost for complications on each branch. A 12-month time frame was used to model the data into a decision tree. Results: Our results found that using Botox first-line had greater cost utility than oxybutynin. The health net benefit calculation showed an increase in 0.22 QALYs when Botox was used first-line. Botox also had greater cost-effectiveness, with the exception of pediatric patients with an ICER of £42,272.14, which is above the NICE threshold of £30,000. Conclusion: Botox was found to be more cost-effective than antimuscarinics in the management of OAB in adults, however less cost-effective in younger patients. This predicates the need for further research to ascertain the age at which Botox becomes cost-effective in the management of OAB. |
format | Online Article Text |
id | pubmed-8394450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83944502021-08-28 Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome Shabir, Habiba Hashemi, Sana Al-Rufayie, Moussa Adelowo, Tayo Riaz, Umar Ullah, Umayair Alam, Benyamin Anwar, Mehreen de Preux, Laure Int J Environ Res Public Health Article Background: The UK National Health Service (NHS) propose the use of oxybutynin prior to onabotulinumtoxinA (Botox) in the management of overactive bladder syndrome (OAB). Oxybutynin is costly and associated with poor adherence, which may not occur with Botox. We conducted a cost-utility analysis (CUA) to compare the medications. Methods: we compared the two treatments in quality-adjusted life years (QALYS), through the NHS’s perspective. Costs were obtained from UK-based sources and were discounted. Total costs were determined by adding the treatment cost and management cost for complications on each branch. A 12-month time frame was used to model the data into a decision tree. Results: Our results found that using Botox first-line had greater cost utility than oxybutynin. The health net benefit calculation showed an increase in 0.22 QALYs when Botox was used first-line. Botox also had greater cost-effectiveness, with the exception of pediatric patients with an ICER of £42,272.14, which is above the NICE threshold of £30,000. Conclusion: Botox was found to be more cost-effective than antimuscarinics in the management of OAB in adults, however less cost-effective in younger patients. This predicates the need for further research to ascertain the age at which Botox becomes cost-effective in the management of OAB. MDPI 2021-08-19 /pmc/articles/PMC8394450/ /pubmed/34444493 http://dx.doi.org/10.3390/ijerph18168743 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shabir, Habiba Hashemi, Sana Al-Rufayie, Moussa Adelowo, Tayo Riaz, Umar Ullah, Umayair Alam, Benyamin Anwar, Mehreen de Preux, Laure Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome |
title | Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome |
title_full | Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome |
title_fullStr | Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome |
title_full_unstemmed | Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome |
title_short | Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome |
title_sort | cost-utility analysis of oxybutynin vs. onabotulinumtoxina (botox) in the treatment of overactive bladder syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394450/ https://www.ncbi.nlm.nih.gov/pubmed/34444493 http://dx.doi.org/10.3390/ijerph18168743 |
work_keys_str_mv | AT shabirhabiba costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT hashemisana costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT alrufayiemoussa costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT adelowotayo costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT riazumar costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT ullahumayair costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT alambenyamin costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT anwarmehreen costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome AT depreuxlaure costutilityanalysisofoxybutyninvsonabotulinumtoxinabotoxinthetreatmentofoveractivebladdersyndrome |